SCHEMBL5085565

SCHEMBL5085565

CCc1c(C(=O)O)c2ccc(O)cc2oc1=O

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B3 P37058 6/20 0.57
KDM4E B2RXH2 4/20 0.56
GLA P06280 4/20 0.56
GAA P10253 4/20 0.56
ALDH1A1 P00352 3/20 0.56
HPGD P15428 3/20 0.56
CASP1 P29466 2/20 0.56
CASP7 P55210 2/20 0.56
HSD17B10 Q99714 2/20 0.56
TSHR P16473 1/20 0.56
NQO1 P15559 1/20 0.56
ESR2 Q92731 2/20 0.54
ESR1 P03372 2/20 0.54
SLC22A12 Q96S37 2/20 0.53
NPSR1 Q6W5P4 2/20 0.53
ERAP1 Q9NZ08 1/20 0.53
MEN1 O00255 1/20 0.50
MGAM O43451 1/20 0.50
NR1I2 O75469 1/20 0.50
LMNA P02545 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2226799 0.89 ESR2 (0.57) HSD17B3KDM4EGLAGAAALDH1A1
SCHEMBL10789370 0.83 ESR2 (0.64) HSD17B3KDM4EGLAGAAALDH1A1
SCHEMBL3761517 0.81 HSD17B3 (0.78) HSD17B3KDM4EGLAGAAALDH1A1
SCHEMBL29725796 0.81 HSD17B3 (0.78) HSD17B3KDM4EGLAGAAALDH1A1
SCHEMBL10651637 0.80 SLC22A12 (0.50) HSD17B3KDM4EGLAGAAALDH1A1
SCHEMBL5751340 0.80 ESR2 (0.57) HSD17B3KDM4EGLAGAAALDH1A1
SCHEMBL10793821 0.78 HSD17B3 (0.74) HSD17B3KDM4EGLAGAAALDH1A1
SCHEMBL10795213 0.78 HSD17B3 (0.74) HSD17B3KDM4EGLAGAAALDH1A1
SCHEMBL3085223 0.78 RXFP1 (0.49) KDM4EGLAGAAALDH1A1HPGD
SCHEMBL10792185 0.78 HSD17B3 (0.71) HSD17B3KDM4EGLAGAAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2007115181-A9 COMPOUNDS EXHIBITING EFFLUX INHIBITOR ACTIVITY AND COMPOSITIONS AND USES THEREOF EASTMAN CHEM CO (US) 2008-04-03 WO disclosed
US-20070254859-A1 Compounds exhibiting efflux inhibitor activity and composition and uses thereof EASTMAN CHEMICAL COMPANY 2007-11-01 US disclosed
WO-2007115181-A2 COMPOUNDS EXHIBITING EFFLUX INHIBITOR ACTIVITY AND COMPOSITIONS AND USES THEREOF EASTMAN CHEMICAL COMPANY (US) 2007-10-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070254859-A1 Compounds exhibiting efflux inhibitor activity and composition and uses thereof ABCC4, NCOA4, NR4A3 HSD17B3 339/4885KDM4E 1065/4885GLA 2694/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.